INTRODUCTION
Abatacept, a fully human fusion protein, is the only biologic for the treatment of rheumatoid arthritis (RA) that selectively modulates the CD80/CD86:CD28 co-stimulatory signal required for full T cell activation and is available in both intravenous and subcutaneous (SC) formulations. The intravenous formulation of abatacept has demonstrated efficacy in several patient populations, including methotrexate-naive patients with early RA [1] and patients with an inadequate response to methotrexate [2] [3] [4] [5] or to anti-tumor necrosis factor therapy [6, 7] . SC abatacept has been shown to be non-inferior to intravenous abatacept [8, 9] . The SC formulation, available as a pre-filled syringe, was first approved in the US in July 2011 for the treatment of moderate-to-severe RA in adults. Since then, SC abatacept has received marketing approval for the treatment of adult RA in numerous regions, including the EU, Japan, Canada, and Australia.
Although the SC delivery method affords users the benefit of self-injection at home, the pre-filled syringe requires several hand manipulations. This can be difficult for individuals with RA, as the disease often affects the small joints of the hand and impairs dexterity. To address this limitation and increase options for patients, a pre-filled, single-use autoinjector for abatacept (ClickJect Ò ; Bristol-Myers Squibb, Princeton, NJ, USA) has been developed, with the aims of increasing the ease of the injection process and minimizing use error risk. The abatacept autoinjector was designed and developed using human factors engineering (HFE). The autoinjector has a large rubberized grip and a hidden needle, and uses an automated injection process including automated delivery of the entire syringe contents. It also incorporates visual feedback to indicate the end of the injection, and shields the needle after injection. These features were designed to facilitate the injection process by improving handling ergonomics and reducing the number of hand manipulations, as well as to help patients who are new to self-injection and to overcome barriers to self-injection such as needle phobia.
This report describes the results of two studies that were conducted to assess the usability and acceptability of the abatacept autoinjector. A formative (pre-validation) study was performed to identify aspects of the product design and instructions for use (IFU) that could be further optimized to reduce the risk of user errors, while a summative study was performed as a final validation of the usability of the product and its labeling. The summative and formative studies were conducted by an independent company, Ipsos-Insight, LLC, separate from the study sponsor (Bristol-Myers Squibb). Participants were informed that the studies were testing a new autoinjector for an RA therapy, but no other specifics were shared. Throughout the studies, participants were blinded to the drug for which the autoinjector was intended, as well as to any sponsor involvement. Informed consent was obtained from all patients for being included in the study; study risks were included in the informed consent.
METHODS

Two
Study Population
To replicate actual use, the study population included individuals from three defined user groups who met the following criteria: (1) [10] .
In each study, users were divided into two groups: trained and untrained ( Fig. 1) . To reduce the potential for use error, users should be trained, by an HCP, on the correct technique for preparing and performing injections when a therapy is prescribed, prior to the first injection. However, because there is no guarantee that all users will be adequately trained before their first use, the device was also validated with untrained participants. For the formative study (Fig. 1a) , the trained arm comprised only patients; for the summative study (Fig. 1b) Table 1 .
Simulated-Use Usability Assessment
Most participants completed each individual step of the simulation task without use errors (Table 2 ). In the formative study, two use errors were observed with the high-priority injection steps, both related to the respondent [one untrained patient and one HCP (i.e., untrained)] not holding the device in place long enough to complete the injection. Although these errors were observed, post-study actions were not taken to modify the device design or labeling, since the root-cause analysis identified the outcome to be a result of the respondents' non-compliance to the protocol and study methodology, rather than a result of mental confusion or physical limitations. However, minor layout changes Table 1 Participant demographics of (A) patients with RA, (B) caregivers, and (C) healthcare professionals In the summative study, all participants except one (an untrained patient) completed all of the high-priority injection steps ( Table 2 ).
The exception related to the 'hold for count and/or wait until blue indicator stops moving'
step. The use error was deemed an artifact of the study, as the patient was currently using a competitor autoinjector and was applying their expectations of the 'feel' in the skin of an injection to indicate the appropriate hold time.
Since this tactile end-of-dose indication does not apply to a simulated-use setting, no mitigation steps were deemed necessary.
Simulated-Use Acceptability Assessment
Average acceptability scores for the device were consistently high for each user group for all measures (comfort, control, ease of use, confidence of dose, overall acceptability) (Table 3 ). In the formative study, all 54 participants responded (34 patients, 10 caregivers, and 10 HCPs); mean overall acceptability scores (out of 7) for patients, caregivers, and HCPs were 6.6, 7.0, and 6.8, respectively. In the summative study, 94 out of 99 participants responded (48 patients, 31 caregivers, and 15 HCPs); mean overall acceptability scores for patients, caregivers, and HCPs were 6.6, 6.8, and 6.8, respectively.
Current Autoinjector User Subgroup Analysis
Among patients who had previously administered injections with a competitor autoinjector, overall mean acceptability ratings were significantly greater for the abatacept autoinjector versus competitor autoinjectors across all user groups in both studies [formative study: patients 6.7 vs 5.2 (P = 0.0001), caregivers 7.0 vs 4.6 (P = 0.0093), HCPs 6.8 vs 5.1 (P = 0.0020); summative study: patients 6.5 vs 5.9 (P = 0.0404), caregivers 6.8 vs 5.8 (P = 0.0047), HCPs 6.8 vs 5.1 (P = 0.0002); Table 4 ]. In the individual categories of comfort, control, ease of use, and confidence of dose, all All values are expressed as mean (standard deviation) Each score was quantified using a 7-point scale, where 1 = very unacceptable, 4 = neutral, and 7 = very acceptable Table 4 Comparative user experience data following abatacept autoinjector use in (A) the formative study or (B) the summative study, from participants who had previously administered injections with an alternative autoinjector Rating Analyses were restricted to those participants who provided both abatacept and competitor autoinjector ratings groups rated the abatacept autoinjector at least the same or superior to competitor autoinjectors; this difference was significant for almost all parameters, across all user groups, and in both studies (Table 4) . Participants demonstrated a strong preference for the abatacept autoinjector over competitor autoinjectors (Table 5) preference data showed at least a trend in favor of the abatacept autoinjector in both studies.
Key Positive Features
In total, 31 formative study participants and 87 summative study participants reported on the positive features of the abatacept autoinjector.
The most frequently noted positive features were: rubberized grip (formative study, noted by 58% of respondents; summative study, 56%), device size (formative, 55%; summative, 52%), visualization of dose progression (window size and location, colored plunger rod; formative, 45%; summative, 57%), button ergonomics (shape, reach, activation force; formative, 19%;
summative, 37%), and ease of use (number of steps, simplicity; formative, 29%; summative, 30%) (Fig. 2 ).
DISCUSSION
The independently conducted studies reported here found that the newly designed autoinjector for the SC delivery of abatacept in patients with RA was easy to use, with low residual risk to users in a real-world setting. Most participants, whether patients, caregivers, or HCPs, trained or untrained, performed all high-priority use steps correctly. Participants rated the abatacept autoinjector highly for user experience in terms of comfort, control, ease of use, confidence of dose, and overall acceptability, with scores nearing the maximum of the 7-point scale used. All user groups across both studies rated the abatacept autoinjector significantly higher than competitor devices for overall acceptability, and when preference data from both studies were combined, significantly more participants in each user group preferred the abatacept autoinjector over their current or most recent device. The drivers for the positive ratings and preference could be grouped into three main categories:
device ergonomics (size, rubberized grip, button reach, force to activate), which provides comfort and security during injection; visualization of dose progression (size and location of window, colored plunger rod), which provides confidence of dose delivery; and simplicity of the process, which contributes to the overall ease of use of the device.
Because RA can affect the small joints of the hands, many patients with RA suffer from compromised dexterity. In addition to interfering with activities of daily living, poor dexterity can affect the ability to perform the steps required for self-injection in patients who would otherwise be eligible for an SC therapy.
Autoinjectors are available for the administration of many SC therapies for chronic conditions, including those in which patients have impaired dexterity [11, 12] . The single-use, pre-filled autoinjector described here was developed following the principles of HFE, to help users to inject one dose of SC abatacept in a home environment. As evidenced by the results of the current studies, the new autoinjector is an important advance for patients receiving, or eligible to receive, SC abatacept, as it increases the ease of the injection process without introducing usability challenges.
In both the formative and summative studies, the vast majority of respondents completed each individual step of the simulated injection without use errors. These results demonstrate that, overall, both trained and untrained users were able to operate the autoinjector safely and effectively to deliver the SC injection by following the IFU.
Furthermore, the overall preference in favor of the abatacept autoinjector over other available injection devices across a range of attributes indicates that the device's features were favored by users with experience of such devices. The fact that similar results were obtained across the two studies provides further credence to these findings. These data also indicate that the device features designed in early development (i.e., shape, rubberized 
CONCLUSIONS
The abatacept autoinjector was found to be highly acceptable against key measures of comfort, control, ease of use, confidence of dose, and overall acceptability in two independently conducted simulated-use studies. High overall acceptability ratings were achieved, and these ratings were significantly greater than those for competitor devices. In addition, a significantly greater number of participants in each user group preferred the abatacept autoinjector over their current or most recent autoinjector.
Participants' positive experiences with the abatacept autoinjector can be attributed to the following key features: device ergonomics (size, shape, rubberized grip, button reach, and activation force), which provides comfort and security during injection; visualization of dose progression (size and location of window, colored plunger rod), which provides confidence of dose delivery; and simplicity of the process, which contributes to the overall ease of use of the device. These results show that HFE optimized the device design and IFU of the abatacept autoinjector to ensure its effective use by patients, caregivers, and HCPs without patterns of preventable use errors.
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